1. Home
  2. PRAX

as of 12-12-2025 3:41pm EST

$267.06
$0.22
-0.08%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Chart Type:
Time Range:
Founded: 2015 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 4.0B IPO Year: 2020
Target Price: $304.43 AVG Volume (30 days): 1.1M
Analyst Decision: Strong Buy Number of Analysts: 14
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -12.92 EPS Growth: N/A
52 Week Low/High: $26.70 - $278.44 Next Earning Date: 11-05-2025
Revenue: $7,463,000 Revenue Growth: 364.98%
Revenue Growth (this year): -96.42% Revenue Growth (next year): -73.33%

AI-Powered PRAX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 76.87%
76.87%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Praxis Precision Medicines Inc. (PRAX)

PRAX Oct 16, 2025

Avg Cost/Share

$111.24

Shares

313,910

Total Value

$33,198,123.57

Owned After

2,361,485

Share on Social Networks: